Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alimta pemetrexed: Phase III data

The open-label, U.S. Phase III PRONOUNCE trial in 361 patients with stage IIIb/IV non-squamous NSCLC showed that first-line treatment with Alimta plus carboplatin followed by Alimta as maintenance therapy missed

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE